| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Galectin-9 an endogenous immunomodulator can normalize skewed immune balance and hence is supposed to have utilities for the treatment of refractory diseases including autoimmunities and cancers. We have been seeing galectin-9 as a promising seed molecule and have been studying it to elucidate the therapeutic mode-of-action and an appropriate disease indication for IND application. Through this research, we uncovered that the mode-of-action included signal transduction through a TNF-receptor superfamily 4-1BB and that the administration of galectin-9 demonstrated unprecedented therapeutic activities including 1)cytotoxicity in drug-resistant colon cancer cells by inducing incomplete autophagy, 2)drastic improvement of survival in an ischemia-reperfusion injury model in mice, 3)reactivation HIV from latently-infected cells and introduction of mutation in the viral genome. These results were summarized in research or patent articles and accepted for publications.
|
